
Last updated: 2026-09-16 09:45:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Eocene Ltd. (EOCN) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $3.63, with a market capitalisation of $4.08M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.49 to $4.88. This page covers its latest market performance, valuation, price trends and company information.
$4.08M | |
$3.58 | |
$4.88 | |
$3.49 | |
$3.82 | |
13.96K | |
65.37K | |
-- | |
$4.88 | |
$3.49 | |
-- | |
-- |
Eocene Ltd. (EOCN) is trading at $4.10 in pre-market trading as of 2026-09-15 23:31:00, up 7.33% ($0.28) from the previous close of $3.82
Pre-market trading shows how investors are pricing EOCN before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Eocene Ltd. (EOCN) moved from $4.03 to $3.63, representing a decline of 9.95% ($0.40).
The stock traded between $3.49 and $4.88 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 65.37 thousand shares, -- versus the previous seven-day period, indicating -- trading activity.
Position in Range: 10.0%
EOCN is currently trading at $3.63, placing it 10.0% of the way from its 52-week low of $3.49 to its 52-week high of $4.88. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Eocene Ltd. (EOCN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.